Sylvant 400mg Powder for Concentrate for Solution for Infusion

Manufacturer
Johnson & Johnson
 
Contents
Siltuximab
 
Indication
Multicentric Castleman’s disease.
 
Instruction
Adult: In patient who are HIV-negative and human herpesvirus-8 (HHV-8) negative: 11 mg/kg, given via infusion over 1 hour every 3 weeks until treatment failure. Interrupt dosing if absolute neutrophil count (ANC) <1,000 cells/mm3; platelet count <75,000 cells/mm3 before the 1st dose or <50,000 cells/mm3 before succeeding doses; Hb <17 g/100 mL. Dose reduction is not recommended.
 
Drug interaction
May decrease serum concentration of CYP3A4 substrate (e.g. warfarin, ciclosporin). May enhance adverse effects of live vaccines. May diminish therapeutic effects of inactivated and live vaccines. May decrease therapeutic effect of oral contraceptives, atorvastatin.